Рекомендации по диагностике и лечению идиопатической тромбоцитопенической пурпуры

Введение. Первичная иммунная тромбоцитопения (ИТП) — это аутоиммунное заболевание, обусловленное выработкой антител к структурам мембраны тромбоцитов и их предшественников — мегакариоцитов, что вызывает не только повышенную деструкцию тромбоцитов, но и неадекватный тромбоцитопоэз, характеризующийся изолированной тромбоцитопенией ниже 100,0×109/л и наличием/отсутствием геморрагического синдрома различной степени выраженности.
Цель — представить современные рекомендации по диагностике и лечению ИТП.
Основные сведения. Рекомендации разработаны на основе опыта российских и международных экспертов, руководства международной рабочей группы по изучению первичной ИТП, рекомендаций европейского и американского обществ гематологов с использованием новых данных о развитии и течении ИТП. Представлены подходы к терапии заболевания с использованием новых лекарственных препаратов из группы агонистов рецепторов тромбопоэтина

1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, defi nitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood. 2009; 113(11): 2386–93. DOI: 10.1182/blood-2008-07-162503.

2. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. Presse Med. 2014; 43(4 Pt2): e49–59. DOI: 10.1016/j.lpm.2014.01.010.

3. Меликян А.Л., Пустовая Е.И., Калинина М.В. и др. Эпидемиологические характеристики первичной иммунной тромбоцитопении у взрослого населения в Российской Федерации. Клиническая онкогематология. 2017;4(10): 558–9.

4. Provan D., Stasi R., Newland A.S., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168–86. DOI: 10.1182/blood-2009-06-225565.

5. Neunert C., Lim W., Crowther M., et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16): 4190–207. DOI: 10.1182/blood-2010-08-302984.

6. Масчан А.А., Румянцев А.Г., Ковалева Л.Г. и др. Рекомендации Российского совета экспертов по диагностике и лечению больных первичной иммунной тромбоцитопенией. Онкогематология. 2010; 3: 36–45.

7. Ковалева Л.Г., Пустовая Е.И., Сафонова Т.И. Идиопатическая тромбоцитопеническая пурпура (ИТП) взрослых. Первичная иммунная тромбоцитопения (ИТП) взрослых. Болезнь Верльгофа. М.: Нью Мун; 2014.

8. Меликян А.Л., Пустовая Е.И., Егорова Е.К. и др. Дифференциальная диагностика тромбоцитопений. Онкогематология. 2017;12(1): 78–87. DOI: 10.17650/1818-8346-2017-12-1-78-87.

9. Provan D., Arnold D., Bussel J.B., et.al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood advances. 2019; 3(22): 3780–808. DOI: 10.1182/bloodadvances-2019000812.

10. Kurokawa T., Ohkohchi N. Ohkohchi. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017; 23(18): 3228–39. DOI: 10.3748/wjg.v23.i18.3228.

11. Protocole national de diagnostic et de soins (PNDS) Purpura thrombopenique immunologiquede l’enfant et de l’adulte. Haute Autoritéde Santé — Mai 2017, 73 p.

12. Carneiro-Sampaio M., Moraes-Vasconcelos D., Kokron C.M., et al. Primary immunodefi ciency diseases in different age groups: a report on 1,008 cases from a single Brazilian reference center. J. Clin. Immunol. 2013; 33(4): 716–24.

13. Michel M., Cooper N., Jean C., et al. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood. 2004; 103(3): 890–6. DOI: 10.11.1182/blood-2003-03-0900.

14. Liu Y., Chen S., Sun Y., et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: A retrospective study. Medicine (Baltimore). 2016; 95(50): e5565.

15. Matzdorff A., Eberl W., Kiefel V., et al. Immunthrombozytopenie (ITP). Onkopedia leitlinien. 2018, 46 p.

16. Wei Y., Ji X.B., Wang Y.W., et.al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016; 127(3): 296–302. DOI: 10.1182/blood-2015-07-659656.

17. Kovaleva L., Apte S., Damodar S., et al. Safety and effi cacy of a 10 % intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies. Immunotherapy. 2016; 8(12): 1371–81.

18. Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Programm. 2012: 191-7. DOI: 10.1182/asheducation-2012.1.191.

19. von dem Borne A.E., Vos J.J., Pegels J.G., et al. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J. 1988; 296(6617): 249–50.

20. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012; 120(5): 960–9. DOI: 10.1182/blood-2011-12-309153.

21. Frenzel W., Wietek S., Svae T.E., et al. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials. Int J Clin Pharmacol Ther. 2016; 54(11): 847–55.

22. Robak T., Salama A., Kovaleva L., et al. Effi cacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009; 14(4): 227–36.

23. Robak T., Mainau C., Pyringer B., et al. Effi cacy and safety of a new intravenous immunoglobulin 10 % formulation (octagam® 10 %) in patients with immune thrombocytopenia. Hematology. 2010; 15(5): 351–9.

24. Cines D.B., McMillan R. Management of adult idiopathic thrombocytopenic purpura. Ann Rev Med. 2005; 56: 425–42. DOI: 10.1146/annurev.med.56.082103.104644.

25. Neunert C., Terrell D.R., Arnold D.M., et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23): 3829– 67. DOI: 10.1182/bloodadvances.2019000966.

26. Carr A.C., Maggini S. Review Vitamin C and Immune Function. Nutrients. 2017; 9: 1211. DOI: 10.3390/nu9111211.

27. Тимирханова Г.А., Абдуллина Г.М., Кулагина И.Г. Витамин С: классические представления и новые факты о механизмах биологического действия. Вятский медицинский вестник. 2007; 4: 158–61.

28. Козярин И.П., Липкан Г.Н., Мвахно А.П. Жгучая, но полезная. Крапива двудомная — лекарственное и пищевое растение (обзор литературы). Гiгiена населених мiсць. 2013; 62: 246–50.

29. Данишян К.И., Соболева О.А., Галстян Г.М. и др. Лапароскопическая спленэктомия при иммунной тромбоцитопенической пурпуре у беременных. Терапевтический архив. 2016; 7: 109–13. DOI: 10.17116/terarkh2016887109-113.

30. Карагулян С.Р., Данишян К.И., Шутов С.А., Силаев М.А. Технические сложности выполнения спленэктомии при заболеваниях системы крови. Клиническая онкогематология. 2017; 10(1): 101–7. DOI: 10.21320/2500-2139-2017-10-1101-107

31. Vianelli N., Palandri F., Polverelli N., et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013; 98(6): 875–80.

32. Vianelli N., Galli M., de Vivo A., et.al, Effi cacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90(1): 72–7.

33. Park Y.H., Yi H.G., Kim C.S., et al. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study. Acta Haematol. 2016; 135(3): 162–71.

34. Tada K., Ohta M., Saga K., et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia. Surg Today. 2018; 48(2): 180–5.

35. Kuter D.J., Bussel J.B., Newland A., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia safety and effi cacy. Br J Haematol. 2013; 161(3): 411–23. DOI: 10.1111/bjh.12260.

36. Newland A., Godeau B., Priego V., et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: fi nal results from a phase 2 study. Br J Haematol. 2016; 172(2): 262–73.

37. Marshall A.L., Scarpone R., De Greef M., et al. Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica. 2016; 101(12): e476–8.

38. Cines D.B., Wasser J., Rodeghiero F., et al. Safety and effi cacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017; 102(8): 1342–51.

39. Saleh M.N., Bussel J.B., Cheng G., et al. Safety and effi cacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the longterm, open-label EXTEND study. Blood. 2013; 121(3): 537–45. DOI: 10.1182/blood-2012-04-425512.

40. Bussel J.B., Saleh M.N., Vasey S.Y., et al. Repeated short-term use of eltrombopagin patients with chronic immune thrombocytopenia (ITP). Br J Haematol. 2013; 160(4): 538–46. DOI: 10.1111/bjh.12169.

41. Cheng G., Saleh M.N., Marcher C., et.al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393–402. DOI: 10.1016/S0140-6736(10)60959-2.

42. Al-Samkari H., Kuter D.J. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018; 84(11): 2673–7.

43. Gonzalez-Lopez T.J., Fernandez-Fuertes F., Hernandez-Rivas J.A., et al. Effi cacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol. 2017; 106(4): 508–16.

44. Tomiyama Y., Miyakawa Y., Okamoto S., et al. A lower starting dose of eltrombopag is effi cacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012; 10(5): 799–806.

45. Gonzalez-Lopez T.J., Alvarez-Roman M.T., Pascual C., et al. Eltrombopag safety and effi cacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol. 2016; 97(3): 297–302.

46. Gonzales-Porras J.R., Mingot-Castellano M.E., Andrade M.M., et al. Use of eltrombopagafter romiplostim in primary immune thrombocytopenia. Br J Hematol. 2015; 169: 111–6. DOI: 10.1111/bjh.13266.

47. Khellaf M., Viallard J.F., Hamidou M., et.al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013; 98(6): 881–7. DOI: 10.3324/haematol.2012.074633.

48. Kuter D.J., Macahilig C., Grotzinger K.M., et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015; 101(3): 255–63.

49. Puavilai T., Thadanipon K., Rattanasiri S., et al. Treatment effi cacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol. 2020; 188(3): 450–9.

50. Chater C., Terriou L., Duhamel A., et al. Reemergence of splenectomy for ITP second-line treatment? Ann Surg. 2016; 264(5): 772–7.

51. Vecchio R., Marchese S., Intagliata E., et al. Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures. J Laparoendosc Adv Surg Tech. 2013; 23(3): 192–8.

52. Boyle S., White R.H., Brunson A., Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013; 121(23): 4782–90.

53. Thai L.H., Mahevas M., Roudot-Thoraval F., et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine. 2016; 95(48): e5098.

54. Choi Y.U., Dominguez E.P., Sherman V., Sweeney J.F. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. JSLS. 2008; 12(3): 314–7.

55. Cervinek L., Cerna O., Caniga M., et al. Effi cacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol. 2012; 96(5): 594–9. DOI: 10.1007/s12185-012-1206-7.

56. Zhou H., Xu M., Qin P., et al. A multicenter randomized open-label study of rituximab plus rhTPOvs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015; 125(10): 1541–7. DOI: 10.1182/blood-2014-06-581868.

57. Khellaf M., Charles-Nelson A., Fain O., et al. Safety and effi cacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014; 124(22): 3228–36. DOI: 10.1182/blood-2014-06-582346.

58. Arnold D.M., Heddle N.M., Carruthers J., et. al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomised patients with immune thrombocytopenia. Blood. 2012; 119: 1356–62.

59. Ghanima W., Khelif A., Waage A., et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicenter, randomised, double blind, placebo-controlled trial. Lancet. 2015; 385: 1653–61. DOI: 10.1016/S0140-6736(14)61495-1.

60. Chugh S., Darvish-Kazem S., Lim W., et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and metaanalysis. Lancet Haematol. 2015; 2(2): e75–e81.

61. Patel V.L., Mahevas M., Lee S.Y., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012; 119(25): 5989–95.

62. Marangon M., Vianelli N., Palandri F., et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017; 98(4): 371–7.

63. Pasa S., Altintas A., Cil T., et al. The effi cacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura. J Thromb Thrombolysis. 2009; 27(3): 329–33.

64. Mahevas M., Ebbo M., Audia S., et al. Effi cacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Am J Hematol. 2013; 88(10): 858–61.

65. Zaja F., Vianelli N., Volpetti S., et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010; 85(4): 329–34.

66. Jurczak W., Chojnowski K., Mayer J., et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018; 183: 479–90.

67. Al-Samkari H., Jiang D., Gernsheimer T., et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022; 197(3): 359–66. DOI: 10.1111/bjh.18081.

68. Al-Samkari H., Nagalla S. Effi cacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets. 2022; 33(2): 257–64. DOI: 10.1080/09537104.2021.1881952

69. Маевская М.В., Жаркова М.С., Ивашкин В.Т. и др. Диагностика расстройств в системе коагуляции, оценка риска геморрагических осложнений при циррозе /заболеваниях печени тяжелого течения по глобальным скрининговым тестам системы гемостаза и принципы их коррекции: методические рекомендации. Медицинский совет. 2022; (15): 70–82. DOI: 10.21518/2079-701X-2022-16-15-70-82.

70. Arnold D.M., Nazi I., Santos A., et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010; 115(1): 29–31.

71. Gomez-Almaguer D., Tarin-Arzaga L., Moreno-Jaime B., et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013; 90(6): 494–500.

72. Gudbrandsdottir S., Birgens H.S., Frederiksen H., et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013; 121(11): 1976–81.

73. Chapin J., Lee C.S., Zhang H., et al. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016; 91(9): 907–11.

74. Bussel J.B., Lee C.S., Seery C., et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014; 99(7): 1264–71.

75. Абузарова Г.Р., Невзорова Д.В., Кумирова Э.В. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016: 94.

76. Piel-Julian M.L., Mahesvas M., Germain J., et al; CARMEN investigators group. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018; 16(9): 1830– 42. DOI: 10.1111/jth.14227.

77. Gernsheimer T., James A.H., Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013; 121(1): 38–47. DOI: 10.1182/blood-2012-08-448944.

78. Васильев С.А., Виноградов В.Л., Мазуров А.В., Маркова М.Л. Тромбоцитопении. Акушерство, гинекология и репродукция. 2014; 2: 112–25.

79. Sukenik-Halevy R., Ellis M.H., Fejgin M.D. Management of immune thrombocytopenic purpura in pregnancy. Obstet Gynecol Sur. 2008; 63(3): 182–8. DOI: 10.1097/OGX.0b013e318164013c.

80. George J.N., Nester C., McIntosh J. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hem Education Program. 2015: 644–8.

81. Fakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci. 2016, 54: 199–202.

82. Кирсанова Т.В., Виноградова М.А., Федорова Т.А. Имитаторы тяжелой преэклампсиии HELLP синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология. 2016; 12: 5–14. DOI: 10.18565/aig.2016.12.5-14.

83. Decroocq J., Marcellin L., Le Ray C., Willems L. Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy. Obstet Gynecol. 2014; 124(2 Pt 2 suppl 1): 481–3.

84. Ferreira I.J.M.C.F., Sousa F., Vasco E.M., et al. Severe immune thrombocytopenia in pregnancy treated with eltrombopag — a case report. J Gynecol Obstet Hum Reprod. 2018; 47(8): 405–8.

85. Chakravarty E.F., Murray E.R., Kelman A., Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011; 117(5): 1499–506.